2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data.

**Natera Inc. (NTRA):  A genetic testing company focused on non-invasive prenatal testing and cancer diagnostics.**

**1. Return Comparison & Alpha/Beta Analysis**

*   **Return Rates:**
    *   NTRA Cumulative Return: 139.49%
    *   VOO (S&P 500) Cumulative Return: 103.47%
    *   Divergence: 36.5 (Relative Divergence: 47.5)

*   **Analysis of Return Rates:** NTRA has significantly outperformed the S&P 500 (VOO) in cumulative return. However, the divergence of 36.5 with a relative divergence of 47.5 suggests the outperformance is not at the top of its historical range and could suggest a period of stabilization after potentially higher highs.

*   **Alpha, Beta, CAGR, and MDD Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | -10.0% | 70.1%  | -34.0%  | -0.2   | 1.2    |
| 2016-2018  | 22.0%  | 80.0%  | 6.0%    | 0.1    | 1.9    |
| 2017-2019  | 50.0%  | 80.0%  | 28.0%   | 1.0    | 4.7    |
| 2018-2020  | 186.0% | 80.5%  | 163.0%  | 1.1    | 13.9   |
| 2019-2021  | 96.0%  | 80.5%  | 49.0%   | 1.6    | 13.0   |
| 2020-2022  | -77.0% | 80.5%  | -76.0%  | 0.1    | 5.6    |
| 2021-2023  | -194.0%| 76.6%  | -195.0% | -1.1   | 8.7    |
| 2022-2024  | 8.0%   | 76.6%  | -13.0%  | -1.2   | 22.1   |
| 2023-2025  | 167.0% | 76.6%  | 99.0%   | 0.1    | 32.6   |

    *   **CAGR (Compound Annual Growth Rate):**  Highly variable, ranging from -194% to +186%.  The last period (2023-2025) shows strong growth again.
    *   **MDD (Maximum Drawdown):**  Consistently high (70.1%-80.5%), indicating significant risk and volatility.
    *   **Alpha:**  Shows how much the stock has outperformed or underperformed its benchmark. Note the large swings (e.g., 163% vs. -195%).
    *   **Beta:**  Measures the stock's volatility relative to the market.  Ranges from -1.2 to 1.6, suggesting the stock can be more or less volatile than the market, with significant periods of both.
    *   **Cap(B):** Market capitalization in Billions

**2. Recent Stock Price Fluctuations**

*   **Current Price:** 233.74
*   **Previous Close:** 235.54
*   **Change:** -0.76
*   **5-day SMA:** 234.442
*   **20-day SMA:** 234.3715
*   **60-day SMA:** 208.4035

*   **Analysis of Price Action:** The current price is slightly below the 5-day and 20-day SMAs, suggesting minor recent weakness. However, it's well above the 60-day SMA, indicating an overall upward trend in the past couple of months. The small price decline from the previous close (-0.76) doesn't indicate a major issue by itself.

**3. Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 34.36 (Approaching oversold, potentially bullish)
*   **PPO:** -0.61 (Slightly negative momentum)
*   **Hybrid Signal:** Buy 100% of cash (Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** -0.1 (Short-term decrease)
*   **Expected Return (%):** -49.9% (Negative expected return compared to S&P 500 if invested long-term)

*   **Analysis of Indicators:**
    *   The MRI suggests a high investment recommendation.
    *   The RSI indicates that the stock might be approaching oversold territory and could be due for a bounce.
    *   The negative PPO suggests some short-term bearish momentum.
    *   The negative expected return is a strong warning sign, suggesting potential underperformance compared to the market.
    *   The Hybrid Signal suggests that current pricing represents a Buy opportunity.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   SWS Partners Bought NTRA Shares
    *   Investor Beat the Market for 3 Decades & is Buying NTRA
    *   Natera Presenting at a Health Conference
    *   Reasons to be a Fan of Natera
    *   Natera Remains a 'Hold' Despite Growth
    *   Analysis: NTRA Could Triple

*   **Analysis of News:** The news is mixed. Positive articles highlight potential growth and institutional buying, while others suggest caution ("Hold" rating). The presentation at a health conference could be a catalyst for increased awareness and potential partnerships. The contrasting opinions suggest uncertainty about the stock's future performance.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 246.26 / 285.00 / 186.00
*   **Recent Rating Changes:** No recent changes available from provided info.

*   **Analysis of Analyst Opinions:**  The analyst consensus is a "Strong Buy," with a significant average target price above the current price. This indicates that analysts, on average, believe the stock is undervalued. However, the wide range in target prices (186 to 285) suggests considerable disagreement on the stock's potential.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-11-07 | -0.64  | 0.59 B$    |
| 2025-08-08 | -0.74  | 0.55 B$    |
| 2025-05-09 | -0.5   | 0.50 B$    |
| 2024-11-12 | -0.26  | 0.44 B$    |
| 2025-11-07 | -0.26  | 0.44 B$    |

*   **Analysis of Earnings:**  Natera is consistently losing money (negative EPS). While revenue is growing, the losses persist. This is a key risk factor.

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $0.59B   | 64.91%        |
| 2025-06-30   | $0.55B   | 63.41%        |
| 2025-03-31   | $0.50B   | 63.12%        |
| 2024-12-31   | $0.48B   | 62.94%        |
| 2024-09-30   | $0.44B   | 61.79%        |

*   **Capital and Profitability:**

| Quarter      | Equity   | ROE        |
|--------------|----------|------------|
| 2025-09-30   | $1.25B   | -6.99%     |
| 2025-06-30   | $1.25B   | -8.10%     |
| 2025-03-31   | $1.24B   | -5.40%     |
| 2024-12-31   | $1.20B   | -4.50%     |
| 2024-09-30   | $0.88B   | -3.60%     |

*   **Analysis of Financials:**
    *   Revenue is consistently growing, and the profit margin is high (61-65%). This is a positive sign, suggesting strong pricing power.
    *   Despite the high-profit margin, the Return on Equity (ROE) is negative, reflecting the overall losses.
    *   Equity is growing indicating a healthy balance sheet.

**7. Comprehensive Analysis (Summary)**

Natera is a high-growth, high-risk company.

*   **Strengths:**
    *   High historical growth compared to the S&P 500.
    *   Strong revenue growth and high-profit margins.
    *   Positive analyst consensus ("Strong Buy").
    *   MRI indicates high investment recommendation.

*   **Weaknesses:**
    *   Consistently negative EPS (losses).
    *   High volatility (high MDD).
    *   Negative expected return compared to the S&P 500 in the long term.
    *   Variable Beta indicating inconsistent correlation with the market.

*   **Overall Assessment:**

    Natera presents a speculative investment opportunity. The company has significant growth potential in a rapidly evolving market (genetic testing). However, the lack of profitability and high volatility are major concerns. The analyst consensus and news headlines are somewhat positive, but the negative expected return is a red flag. Investors should carefully weigh the risks and rewards before investing in NTRA.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.